MoonLake Immunotherapeutics Ownership | Who Owns MoonLake Immunotherapeutics?

MoonLake Immunotherapeutics Ownership Summary

MoonLake Immunotherapeutics is owned by 100.52% institutional investors, 15.23% insiders. Bvf inc/il is the largest institutional shareholder, holding 31.40% of MLTX shares. T. Rowe Price Health Sciences is the top mutual fund, with 2.32% of its assets in MoonLake Immunotherapeutics shares.

MLTX Ownership Benchmark

Type	Name	% Inst	% Insiders	% Retail
Stock	MoonLake Immunotherapeutics	100.52%	15.23%	-15.75%
Sector	Healthcare Stocks	57.39%	9.93%	32.68%
Industry	Biotech Stocks	68.48%	9.65%	21.87%

Institutional Shareholders

Top Institutional Shareholders by Total Shares

Holder	Shares	% Holding	Value
Bvf inc/il	19.75M	31.40%	$1.07B
Cormorant asset management, lp	8.49M	13.50%	$459.96M
Fmr	6.34M	10.08%	$343.39M
Price t rowe associates inc /md/	3.34M	5.32%	$181.06M
Avoro capital advisors	2.77M	4.40%	$150.00M
Paradigm biocapital advisors lp	1.77M	2.82%	$95.97M
Goldman sachs group	1.67M	2.66%	$90.68M
Holocene advisors, lp	1.59M	2.52%	$85.84M
Westfield capital management co lp	1.31M	2.09%	$71.02M
Federated hermes	1.28M	2.04%	$69.31M

Top Institutional Shareholders by % of Total Assets

Holder	Shares	% Assets	Value
Bvf inc/il	19.75M	36.25%	$1.07B
Cormorant asset management, lp	8.49M	25.26%	$459.96M
Saturn v capital management	346.11K	7.34%	$18.74M
Ghost tree capital	300.00K	4.13%	$13.19M
5am venture management	282.31K	3.65%	$15.29M
Paradigm biocapital advisors lp	1.77M	3.34%	$95.97M
Bioimpact capital	315.23K	2.42%	$17.07M
Avoro capital advisors	2.77M	2.12%	$150.00M
Nationale-nederlanden powszechne towarzystwo emerytalne	228.80K	1.64%	$10.06M
Finepoint capital lp	447.94K	1.48%	$24.26M

Top Buyers

Holder	Shares	% Assets	Change
Fmr	6.34M	0.02%	1.39M
Paradigm biocapital advisors lp	1.77M	3.34%	840.73K
Polar capital	1.10M	0.33%	600.00K
Price t rowe associates inc /md/	3.34M	0.02%	363.39K
Ecor1 capital	332.52K	0.68%	332.52K

Top Sellers

Holder	Shares	% Assets	Change
Bvf inc/il	19.75M	36.25%	-2.00M
T. rowe price investment management	-	-	-1.10M
Logos global management lp	-	-	-750.00K
Adage capital partners gp	155.00K	0.01%	-350.00K
Perceptive advisors	-	-	-339.01K

New Positions

Holder	Shares	% Assets	Change	Value
Ecor1 capital	332.52K	0.68%	332.52K	$18.01M
Point72 asset management	98.72K	0.01%	98.72K	$5.35M
Dimensional fund advisors lp	64.38K	0.00%	64.38K	$3.49M
Peak6 investments	13.00K	0.00%	13.00K	$571.61K
Caption management	12.37K	0.01%	12.37K	$669.89K

Sold Out

Holder	Change
Clear street markets	-90.00
New york state common retirement fund	-140.00
Kbc group nv	-565.00
Entrypoint capital	-862.00
Tower research capital llc (trc)	-1.67K

Institutional Ownership Trends

Date	Holdings	Change %	Shares	Change %	Ownership	Change %	Increased Position	Change %	Decreased Position	Change %
Dec 31, 2024	124	6.90%	63,224,599	1.80%	100	1.03%	70	-	30	20.00%
Sep 30, 2024	116	-1.69%	62,108,663	2.42%	98	1.05%	71	20.34%	25	-35.90%
Jun 30, 2024	118	-9.92%	60,643,906	2.22%	96	1.08%	59	-6.35%	39	-7.14%
Mar 31, 2024	131	-11.49%	59,326,406	-0.00%	94	0.97%	63	-30.77%	42	20.00%
Dec 31, 2023	148	12.12%	59,328,271	5.33%	99	0.89%	91	13.75%	35	29.63%

Top Mutual Funds Shareholders

Holder	Shares	% Holding	Change
T. Rowe Price Health Sciences	1.47M	2.32%	-93.40K
Polar Capital Biotech S Inc	1.00M	1.58%	-
Fidelity Select Health Care	752.79K	1.19%	-
Westfield Capital Mgt Co Sm-Cap Gr Eq	704.82K	1.11%	56.75K
Harbor Small Cap Growth Instl	704.82K	1.11%	56.75K
Fidelity Growth Compy Commingled Pl S	687.62K	1.09%	2.62K
US Small-Cap Growth II Equity Comp	667.18K	1.06%	-574.00
Federated Hermes Kaufmann R	665.00K	1.05%	110.00K
Federated Hermes Kaufmann Growth	665.00K	1.05%	110.00K
T. Rowe Price New Horizons	666.98K	1.05%	-

Recent Insider Transactions

Date	Name	Role	Activity	Value
Oct 04, 2024	BVF PARTNERS L P/IL		Sell	$6.63M
Oct 04, 2024	BVF PARTNERS L P/IL		Sell	$41.84M
Oct 04, 2024	BVF PARTNERS L P/IL		Sell	$51.53M
Oct 04, 2024	Sturge Simon	-	Sell	$9.19M
Feb 29, 2024	Santos da Silva Jorge	Chief Executive Officer	Sell	$264.92K

Insider Transactions Trends

Date	Buy	Sell
2024 Q2	-	-
2024 Q1	-	21
2023 Q4	4	2
2023 Q2	28	-
2022 Q2	1	-

MLTX Ownership FAQ

Who Owns MoonLake Immunotherapeutics?

MoonLake Immunotherapeutics shareholders are primarily institutional investors at 100.52%, followed by 15.23% insiders and -15.75% retail investors. The average institutional ownership in MoonLake Immunotherapeutics's industry, Biotech Stocks , is 68.48%, which MoonLake Immunotherapeutics exceeds.

Who owns the most shares of MoonLake Immunotherapeutics?

MoonLake Immunotherapeutics’s largest shareholders are Bvf inc/il (19.75M shares, 31.40%), Cormorant asset management, lp (8.49M shares, 13.50%), and Fmr (6.34M shares, 10.08%). Together, they hold 54.99% of MoonLake Immunotherapeutics’s total shares outstanding.

Does Blackrock own MoonLake Immunotherapeutics?

BlackRock is not among the top 10 institutional shareholders of MoonLake Immunotherapeutics.

Who is MoonLake Immunotherapeutics’s biggest shareholder by percentage of total assets invested?

Bvf inc/il is MoonLake Immunotherapeutics’s biggest shareholder by percentage of total assets invested, with 36.25% of its assets in 19.75M MoonLake Immunotherapeutics shares, valued at 1.07B$.

Who is the top mutual fund holder of MoonLake Immunotherapeutics shares?

T. Rowe Price Health Sciences is the top mutual fund holder of MoonLake Immunotherapeutics shares, with 2.32% of its total shares outstanding invested in 1.47M MoonLake Immunotherapeutics shares.

Try Tickergate Pro Free

Customize Everything. 100% Flexibility. Fast and Easy to Use (No code or Excel Needed)

Customize your own personal stocks lists, views and charts
Choose from hundreds of fields, up to 15 years of history
Conduct deep comparison analysis

Discover trending investment themes
Find your next best investment
Research stocks using tools